menu
    • menu
    [{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Private Placement","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"RZ-001","moa":"hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Charles River","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"RZ-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rznomics \/ Charles River","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Charles River"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"RZ-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"RZ-001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenVivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"GVO-1102","moa":"","graph1":"Technology","graph2":"Approved","graph3":"GenVivo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"GenVivo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GenVivo \/ Not Applicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viracta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"RZ-001","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rznomics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Valcyte

    Menu

    Valcyte

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rznomics

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            Rznomics

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rznomics Secures Expanded Access for Glioblastoma Patients with Novel Therapy

                            Details : RZ-001 is an anti-HCC activity by suppressing hTERT expression selectively in cancer cells. It is being in combination With valganciclovir for the treatment in 18 and older with Glioblastoma.

                            Brand Name : RZ-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 25, 2024

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viracta Announces Positive Data from NAVAL-1 Trial and Updated Nana-val Development Plan

                            Details : Viracta's lead program, Nana-Val evaluates the all-oral combination of nanatinostat & valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.

                            Brand Name : Nana-Val

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 14, 2024

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GenVivo

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            GenVivo

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GVO-1102,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenVivo Begins Patient Dosing in Phase I/Ib Trial for GEN2 Gene Vector Immunotherapy

                            Details : GEN2’s dose-escalation trial, GVO-1102 non-replicating immunotherapy vector administered by intravenous infusion with valganciclovir for the treatment of patients suffering from neoplasms.

                            Brand Name : GVO-1102

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 27, 2024

                            Lead Product(s) : GVO-1102,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viracta Reports Positive Results in NAVAL-1 Trial for EBV+ Lymphoma

                            Details : Viracta’s lead program VRx-3996 combines nanatinostat and valganciclovir in a Phase 2 trial for EBV-positive relapsed/refractory lymphoma, aiming to address unmet patient needs.

                            Brand Name : VRx-3996

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viracta Completes Enrollment in NAVAL-1 Trial for Peripheral T-Cell Lymphoma

                            Details : Nana-val (nanatinostat with valganciclovir) is an all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for EBV+ peripheral T-cell lymphoma.

                            Brand Name : Nana-val

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 29, 2024

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rznomics

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            Rznomics

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rznomics Secures Orphan Drug Designation for RZ-001 in Hepatocellular Carcinoma

                            Details : RZ-001, which selectively suppresses hTERT expression in cancer cells, is under Phase 1/2 clinical trials combined with valganciclovir for hepatocellular carcinoma.

                            Brand Name : RZ-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 02, 2024

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment o...

                            Details : Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for the treatment of EBV-related nasopharyngeal carcinoma.

                            Brand Name : Nana-val

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 12, 2023

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstei...

                            Details : Nana-val (nanatinostat + valganciclovir) is a combination medicine. Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor. It is being evaluated in phase 1/2 clinical trials for the treatment of Epstein-Barr Virus-positive solid tumors...

                            Brand Name : Nana-val

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 04, 2023

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Rznomics

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            Rznomics

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001

                            Details : RZ-001, the RNA replacement enzyme-based cancer gene therapy for the treatment of GBM, targets and cleaves hTERT mRNA and replaces the mRNA with the therapeutic gene RNA.

                            Brand Name : RZ-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 10, 2023

                            Lead Product(s) : RZ-001,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Viracta Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refract...

                            Details : Nana-val (nanatinostat) is an oral histone deacetylase inhibitor, selective for specific Class I HDACs isoform. It is currently being investigated in combination with valganciclovir for R/R EBV+ PTCL.

                            Brand Name : Nana-Val

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 28, 2023

                            Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth